<DOC>
	<DOCNO>NCT02112812</DOCNO>
	<brief_summary>A high prevalence Helicobacter pylorus infection rate demonstrate among PD patient compare control . As H. pylori infection know interfere levodopa absorption , embark study understand effect Helicobacter pylori infection eradication among select Malaysian population Parkinsons disease , relation levodopa effectiveness motor improvement . The study hypotheses : 1 . H. pylori eradication improve L-dopa 'onset ' time prolongs L-dopa 'on-time ' duration . 2 . PD patient H. pylori infection show clinical improvement motor disability quality life eradication therapy H. pylorus , assess use UPDRS-III / PDQ39 questionnaire .</brief_summary>
	<brief_title>Effects Helicobacter Pylori Infection Eradication Patients With Parkinson 's Disease</brief_title>
	<detailed_description>Study Background The early observation association H. pylorus PD 1966 Strang find gastric duodenal ulcer common PD patient age gender-matched control ulcer precede diagnosis PD 20 year . Upon discovery H. pylori association peptic ulcer disease , numerous study conduct look correlation H. pylorus PD . James Parkinson consider may association PD gastrointestinal pathology write `` Although unable trace connection disorder state stomach bowel may induce morbid action part medulla spinalis , …little hesitation need employ determine probability occurrence '' ( pg 64 , The Shaking Palsy ) . A direct causal relationship hypothesise Altschuler propose H. pylorus might play part biosynthetic route MPTP MPTP-like substance direct neurotoxic effect dopaminergic neuron . In 1999 , Charlett et al . observe cardinal feature PD , namely bradykinesia , rigidity abnormal posture significantly prevalent sibling PD patient compare control . Positive H. pylorus serology find 70 % PD patient 63 % sibling compare 36-43 % control . They conclude familial transmission H. pylorus might account significantly high prevalence parkinsonism sibling PD patient . Bjarnason et al find presence antibody H. pylorus correlate IPD , eradication show improvement measurement stride length . There also correlation eradication therapy reduction inflammatory marker IL-6 TNF-alpha . They hypothesise chronic infection lead underlie chronic inflammatory autoantibody /molecular mimicry mechanism lead destruction dopaminergic neuron . Hirai study lipid composition H. pylorus identify three cholesterol glucosidases ( CG ) . Of interest , similarity structure CG sterols H. pylorus sterol glucosidase cycad , may hypothesize possibility H. pylori certain strain cause parkinsonism way produce similar sterol glucosidase neurotoxic . Cycad type seed make flour know cause ALS-PD disease population Guam island Kii , Japan . Murine experimental exposure cycad show progressive motor cognitive deterioration . Pathological analysis reveal loss motor neurones loss striatal dopaminergic terminal . Levodopa absorption occur duodenum . In advanced PD , gastric motility impair delay transit levodopa pylorus subsequently , prevent delay clinical effect . In duodenum , inflammatory pathology also impair levodopa absorption . H.pylori infection affect L-dopa bioavailability via disruption duodenal mucosa , site absorption local production reactive oxygen specie , may inactivate drug . Irregularity levodopa delivery brain common PD lead erratic response levodopa motor fluctuation . This attribute impaired gastrointestinal transit absorption drug . Pierantozzi et al . conduct study PD patient H. pylori infection randomise eradication therapy control group . Serum levodopa level consistently high eradication therapy group compare control . The active group also note prolonged clinical response levodopa , `` time '' few motor fluctuation . The author conclude H. pylori infection impairs absorption levodopa eradication therapy simple inexpensive mean aid levodopa absorption improve clinical response . Study justification Diagnosing H.pylori infection Parkinson 's patient important eradicate H. pylorus reduces risk H. pylorus complication duodenal ulcer gastric carcinoma , also help improve motor disability . Previous study abroad show eradication H. pylorus increase levodopa bioavailability H. pylori show affect absorption . Conducting study among Parkinson 's patient PPUKM give u data Malaysian population . Study Objectives Primary Objectives : To compare clinical response L-dopa H. pylorus eradication therapy H. pylorus infect PD group . ( L-dopa 'onset ' time ( minute ) L-dopa 'on-time ' duration ( minute ) ) . Secondary Objectives : To assess clinical motor improvement H. pylori eradication therapy infect PD group , use UPDRS-III PDQ39 questionnaire . Study design study population . This prospective study , conduct UKMMC month January 2012 June 2012 . The study population consist Parkinson 's disease patient levodopa therapy , consecutively recruit neurology outpatient clinic UKMMC . The study do approval Research Ethics Committee UKMMC . Patients fulfill inclusion exclusion criterion counsel upon give informed consent , enrol study . Individuals poor command English Bahasa Malaysia give explanation assistance interpreter . Study protocol study tool Upon consent , patient enquire regard background data record Information regard sociodemographic characteristic ( smoke history , alcohol consumption coffee consumption ) , previous antibiotic use , concomitant medical condition , current medication gastrointestinal symptom record . Height weight measure record data collection sheet . The clinical response L-dopa document ( look L-dopa 'onset ' time ( minute ) L-dopa 'on-time ' duration ( minute ) ) . The severity Parkinson 's disease assess use PDQ-39 questionnaire Unified Parkinson 's Disease Rating Scale ( UPDRS ) -III . Urea Breath test protocol Each subject undergo UBT diagnose H. pylori infection . UBT select appropriate tool diagnose H. pylorus study noninvasive , non-radiotoxic readily available compare OGDS . Serology test cheaper widely accessible use many research locally internationally . Unfortunately , serology test specificity 79-90 % sensitivity 76-84 % . Furthermore , patient positive H. pylorus remain seropositive long 4 year eradication even UBT long negative . Subjects PPIs H2 blocker give later appointment UBT 4 week stop medication . Each patient give 75 mg IRIS 13C urea mixed Tang™ Orange juice . Breath sample take 0 minute , 10 minute , 20 minute 30 minute . At breath , subject ask inhale deeply hold 5 second blow slowly bag fully inflate . The breath sample collect analysed use Non-Dispersive Isotope-Selective InfraRed Spectrometer ( NDRIS ) [ IRIS ] . Interpretation result base IRIS Software 2.3 analysis Delta ( δ ) baseline ( DOB ) Treatment H. pylorus Patients positive Urea Breath Test ( positive H. pylorus infection ) start eradication therapy H. pylorus ( oral esomeprazole 40mg twice bd , oral clarithromycin 500mg bd oral amoxicillin 1000mg bd ) 14 day . This current recommendation formulate Maastricht III Consensus Conference March 2005 . Follow visit H pylori-infected Parkinsons disease patient follow neurology clinic 3 month eradication therapy H pylorus . The clinical response L-dopa eradication treatment H pylorus assess ( look L-dopa 'onset ' time ( minute ) L-dopa 'on-time ' duration ( minute ) ) . The clinical motor improvement also assess use PDQ-39 questionnaire Unified Parkinson 's Disease Rating Scale ( UPDRS ) -III . Patients guide investigator answer questionnaire . Ethical Consideration This study conduct approval PPUKM ethic committee . Participants explain regard procedure benefit study sign consent form . They allow opt study point wish .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<criteria>Diagnosis idiopathic Parkinson 's disease ( PD ) neurologist Age 18 year Written inform consent give either patient next kin Patient LDOPA therapy Patients diagnosis secondary parkinsonism , Parkinson 's plus syndrome History recent proton pump inhibitor ( PPIs ) Histamine ( H2 ) antagonist use least 4 week prior urea breath test History recent antibiotic use ( less 6 month ) Inability perform urea breath test</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Parkinsons disease</keyword>
	<keyword>Helicobacter pylorus</keyword>
	<keyword>Eradication</keyword>
	<keyword>Levodopa response</keyword>
	<keyword>Motor outcome</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Open label</keyword>
</DOC>